Bicyclonucleoside and oligonucleotide analogue

Details Bicyclonucleoside and oligonucleotide analogue Bicyclonucleoside and oligonucleotide analogue

2001-12-28

2004-08-03

Wilson, James O. (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S026700, C536S026800, C536S026900, C536S027100, C536S027200, C536S028100, C536S028400

Reexamination Certificate

active

06770748

ABSTRACT:

TECHNICAL FIELD
This invention relates to a novel nucleoside analogue and a novel nucleotide analogue, and more particularly, to a nucleotide analogue suitable as an antisense molecule.
BACKGROUND ART
In 1978, it was reported for the first time that an antisense molecule inhibited influenza virus infection. Since then, reports have been issued that antisense molecules inhibited the expression of oncogenes and AIDS infection. In recent years, antisense oligonucleotides have become one of the most promising pharmaceuticals, because they specifically control the expression of undesirable genes.
The antisense method is based on the idea of controlling a unidirectional flow called the central dogma, i.e., DNA→RNA→protein, by use of an antisense oligonucleotide.
When a naturally occurring oligonucleotide was applied to this method as an antisense molecule, however, it was decomposed with various nucleases in vivo, or its permeation through the cell membrane was not high. To solve these problems, numerous nucleic acid derivatives and analogues have been synthesized, and their studies have been conducted. Examples of the synthesized products include a phosphorothioate having a sulfur atom substituting for an oxygen atom on the phosphorus atom, and a methylphosphonate having a substituting methyl group. Recently, products have been synthesized in which the phosphorus atom has also been substituted by a carbon atom, or the structure of the sugar portion has been changed, or the nucleic acid base has been modified. Any resulting derivatives or analogues, however, have not been fully satisfactory in terms of in vivo stability, ease of synthesis, and sequence specificity (the property of selectively controlling the expression of a particular gene alone).
Under these circumstances, there has been a demand for the creation of an antisense molecule which is minimally decomposed with a nuclease in vivo, binds to target messenger RNA with high affinity, has high specificity, and can thus efficiently control the expression of a particular gene.
DISCLOSURE OF THE INVENTION
The inventors of the present invention designed a nucleic acid analogue with immobilized conformation of the sugar portion in a nucleic acid, which would be useful in the antisense method. They synthesized a nucleoside analogue which will be a unit structure therefor, and confirmed that an oligonucleotide analogue prepared using it was very useful as an antisense molecule.


REFERENCES:
patent: 5859221 (1999-01-01), Cook et al.
patent: 6268490 (2001-07-01), Imanishi et al.
patent: 9747636 (1997-12-01), None
Obika et al., “Synthesis of 2′-O,4′-C -Methyleneuridine and -cytidine. Novel Bicyclic Nucleosides Having a Fixed C3, -endo Sugar Puckering,”Tetrahedron Letters, 38(50), 8735-8738 (Dec. 15, 1997).
Altmann et al., “6′-Carbon-Substituted Carbocyclic Analogs of 2′-Deoxyribonucleosides—Synthesis and Effect on DNA/RNA Duplex Stability,”Tetrahedron, 52(39), 12699-12722 (1996).
Nielsen et al., “Synthesis and Chemoselective Activation of Phenyl 3,5-Di-O-benzyl-2-O,4-C-methylene-1-thio-&bgr;-D-ribofuranoside: A Key Synthon Towards &agr;-LNA,”Chemical Communications,(Issue No. 23), 2645-2646 (Dec. 7, 1998).
Herdewijn, “Targeting RNA with Conformationally Restricted Oligonucleotides,”Liebigs Annalen,(Issue No. 9), 1337-1348 (Sep., 1996).
Beaucage, “Oligonucleotide Synthesis—Phosphoramidite Approach,” Ch. 3 inMethods in Molecular Biology, vol. 20: Protocols for Oligonucleotide and Analogues,S. Agrawal (ed.), 1993, Humana Press, Totowa, NJ, pp. 33-61.*
Beaucage et al. (I), “Advances in the Synthesis of Oligonucleotides by the Phosphoramidite Approach,” (Tetrahedron Report No. 309)Tetrahedron, 48(12), 2223-2311 (1992).*
Beaucage et al. (II), “The Synthesis of Modified Oligonucleotides by the Phosphoramidite Approach and Their Applications,”Tetrahedron, 49(28), 6123-6194 (1993).*
Lehninger et al.,Principles of Biochemistry, Second Edition,Worth Publishers, 1993, only pp. 324-327 supplied.*
Sanghvi, “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonuceotides,” Ch. 15 inAntisense Research and Applications,Crooke & LeBleu (eds.), CRC Press, Boca Raton, FL, 1993, pp. 273-288.*
Singh, et al., LNA (locked Nucleic Acids): Synthesis and High-Affinity Nucleic Acid Recognition, Chemical Communications, 1998, 455-456, 4 (Feb. 21, 1998).

Affiliated with

Also associated with

Rating

Bicyclonucleoside and oligonucleotide analogue does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclonucleoside and oligonucleotide analogue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclonucleoside and oligonucleotide analogue will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3357953